Brief: Sigilon Therapeutics Announces Clinical Hold On Sig-001 Phase 1/2 Study In Hemophilia A

Sigilon Therapeutics

09/07/2021 12:54

July 9 (Reuters) - Sigilon Therapeutics Inc  SGTX.O :
    * SIGILON THERAPEUTICS ANNOUNCES CLINICAL HOLD ON SIG-001
PHASE
1/2 STUDY IN HEMOPHILIA A
    * SIGILON THERAPEUTICS INC -  CLINICAL HOLD WAS INITIATED
FOLLOWING COMPANY'S SUBMISSION OF A SERIOUS ADVERSE EVENT
    * SIGILON THERAPEUTICS INC - CLINICAL HOLD WAS INITIATED
FOLLOWING
SAE AND TEMPORARY ENROLLMENT HALT TO FDA AND OTHER REGULATORY
AGENCIES.
    * SIGILON THERAPEUTICS INC - STATUS OF SAE INVESTIGATION
WILL
CONTINUE TO BE REVIEWED BY SAFETY REVIEW COMMITTEE FOR SIG-001

Source text for Eikon:  ID:nGNX2pxBdW 
Further company coverage:  SGTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))